These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 27680683)

  • 1. Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.
    Xia T; Konno H; Barber GN
    Cancer Res; 2016 Nov; 76(22):6747-6759. PubMed ID: 27680683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian Cancer Cells Commonly Exhibit Defective STING Signaling Which Affects Sensitivity to Viral Oncolysis.
    de Queiroz NMGP; Xia T; Konno H; Barber GN
    Mol Cancer Res; 2019 Apr; 17(4):974-986. PubMed ID: 30587523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma.
    Bommareddy PK; Zloza A; Rabkin SD; Kaufman HL
    Oncoimmunology; 2019; 8(7):1591875. PubMed ID: 31143509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talimogene laherparepvec (T-VEC) as cancer immunotherapy.
    Kohlhapp FJ; Zloza A; Kaufman HL
    Drugs Today (Barc); 2015 Sep; 51(9):549-58. PubMed ID: 26488034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.
    Johnson DB; Puzanov I; Kelley MC
    Immunotherapy; 2015; 7(6):611-9. PubMed ID: 26098919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nectin-1 Expression Correlates with the Susceptibility of Malignant Melanoma to Oncolytic Herpes Simplex Virus In Vitro and In Vivo.
    Schwertner B; Lindner G; Toledo Stauner C; Klapproth E; Magnus C; Rohrhofer A; Gross S; Schuler-Thurner B; Öttl V; Feichtgruber N; Drexler K; Evert K; Krahn MP; Berneburg M; Schmidt B; Schuster P; Haferkamp S
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
    Gangi A; Zager JS
    Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ; Kaufman HL
    Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production.
    Konno H; Yamauchi S; Berglund A; Putney RM; Mulé JJ; Barber GN
    Oncogene; 2018 Apr; 37(15):2037-2051. PubMed ID: 29367762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Talimogene Laherparepvec: First Global Approval.
    Greig SL
    Drugs; 2016 Jan; 76(1):147-54. PubMed ID: 26620366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
    Dummer R; Hoeller C; Gruter IP; Michielin O
    Cancer Immunol Immunother; 2017 Jun; 66(6):683-695. PubMed ID: 28238174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.
    Hoffner B; Iodice GM; Gasal E
    Oncol Nurs Forum; 2016 Mar; 43(2):219-26. PubMed ID: 26906132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells.
    Ahn J; Xia T; Rabasa Capote A; Betancourt D; Barber GN
    Cancer Cell; 2018 May; 33(5):862-873.e5. PubMed ID: 29706455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity.
    Falahat R; Perez-Villarroel P; Mailloux AW; Zhu G; Pilon-Thomas S; Barber GN; Mulé JJ
    Cancer Immunol Res; 2019 Nov; 7(11):1837-1848. PubMed ID: 31462408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First Oncolytic Viral Therapy for Melanoma.
    Poh A
    Cancer Discov; 2016 Jan; 6(1):6. PubMed ID: 26552414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human dendritic cells efficiently phagocytose adenoviral oncolysate but require additional stimulation to mature.
    Schierer S; Hesse A; Knippertz I; Kaempgen E; Baur AS; Schuler G; Steinkasserer A; Nettelbeck DM
    Int J Cancer; 2012 Apr; 130(7):1682-94. PubMed ID: 21557217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With Tumorigenesis.
    Xia T; Konno H; Ahn J; Barber GN
    Cell Rep; 2016 Jan; 14(2):282-97. PubMed ID: 26748708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.
    Garnock-Jones KP
    BioDrugs; 2016 Oct; 30(5):461-468. PubMed ID: 27516203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms and pathways of innate immune activation and regulation in health and cancer.
    Cui J; Chen Y; Wang HY; Wang RF
    Hum Vaccin Immunother; 2014; 10(11):3270-85. PubMed ID: 25625930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.